The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Validation of p95 as a predictive marker for trastuzumab-based therapy in primary HER2-positive breast cancer: A translational investigation from the neoadjuvant GeparQuattro study.
S. Loibl
No relevant relationships to disclose
J. Bruey
Employment or Leadership Position - bioTheranostics
G. Von Minckwitz
No relevant relationships to disclose
J. B. Huober
Consultant or Advisory Role - GlaxoSmithKline; Roche
Research Funding - GlaxoSmithKline
M. F. Press
No relevant relationships to disclose
S. Darb-Esfahani
No relevant relationships to disclose
C. Solbach
No relevant relationships to disclose
C. Denkert
No relevant relationships to disclose
H. Tesch
No relevant relationships to disclose
F. Holms
No relevant relationships to disclose
T. N. Fehm
No relevant relationships to disclose
K. Mehta
No relevant relationships to disclose
M. Untch
No relevant relationships to disclose